Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

 Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

Shots:

  • The PIONEER-HF 4-week extension study involves assessing Entresto vs Enalapril in ~832 patients with systolic heart failure treated with Entresto for the first 8 wks.& the last 4wks and with enalapril and then switched to Entresto for the last 4wks.
  • The PIONEER-HF 4-week extension study results: change in NT-proBNP (-18.5% vs -35.8%); symptomatic hypotension (2.9% vs 3.9%); hyperkalemia (2.4% vs 4.1%); Worsening renal function (8.6% vs 9.6%); no angioedema events; @12 wks. relative risk reduction 33%
  • Entresto (sacubitril/valsartan, bid, 50/100/200 mg) is a heart failure therapy used to reduce the strain on failing heart by improving neurohormonal systems and inhibiting the effect of overactive RAAS

Click  here to read full press release/ article | Ref: Novartis | Image: Daily Record 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post